Dear Molecular Imaging Insider,
In the U.S., oncology staging and myocardial perfusion studies have been the domain of PET and PET/CT. The technology is also poised to occupy center stage in dementia imaging, once the final hurdles to the implementation of the National Oncologic PET Registry (NOPR) are cleared. What's next on the horizon for the modality?
A multidisciplinary group of researchers may have expanded the potential for PET and PET/CT by developing a protocol to predict the efficacy of drug therapy in oncology patients. Raymond Muzic, Ph.D., from Case Western Reserve University in Cleveland, presented the results of a C-11 topotecan PET study at the recent Academy of Molecular Imaging conference in Orlando, FL.
The scientists hypothesized that radio-labeling topotecan, a second-line drug used in the treatment of ovarian and small cell lung cancer, would enable them to predict its effectiveness in treating these metastatic diseases. In the process of creating the protocol to conduct their study, the researchers may have developed a technique that could be applied to a wide range of oncologic drug therapies.
To read more about how C-11 topotecan was used to predict therapeutic outcomes, click here. As a Molecular Imaging Insider subscriber, you have access to this story before it's published for the rest of our AuntMinnie.com members.
If you'd care to share your suggestions or insights on any aspect of molecular imaging you'd like to see covered on AuntMinnie.com in the future, please contact me. I look forward to hearing from you.
